Development of a recombinant vaccine against human onchocerciasis.
David AbrahamJohn Graham-BrownDarrick CarterSean A GrayJessica A HessBenjamin L MakepeaceSara LustigmanPublished in: Expert review of vaccines (2021)
The adjuvanted O. volvulus vaccine composed of two antigens Ov-103 and Ov-RAL-2 was shown to be consistently effective at inducing protective immunity using multiple immune mechanisms. The vaccine is ready for further evaluation in other animal models before moving to clinical trials in humans.